SYNGAP1 Mutation in Focal and Generalized Epilepsy: A Literature Overview and A Case Report with Special Aspects of the EEG

 

 Buy Article Permissions and Reprints

Abstract

Background SYNGAP1, which encodes a RAS-GTPase-activating protein, is located on the short arm of chromosome 6. Heterozygous SYNGAP1 gene mutations have been associated with autism spectrum disorders, delay of psychomotor development, acquired microcephaly, and several forms of idiopathic generalized epilepsy. Here, we report a patient with a new SYNGAP1 stop mutation, and compare the phenotype with published cases with SYNGAP1 mutations and epilepsy.

Patient This 15-year-old nondysmorphic girl with intellectual disability developed drop attacks at the age of 2 years, later clonic and clonic–tonic as well as myoclonic seizures predominantly during sleep. The epilepsy was well-controlled by valproic acid (VPA) and later on with levetiracetam. Electroencephalogram (EEG) showed a complete EEG-normalization with eye opening as well as photosensitivity. Magnetic resonance imaging was normal. Genetic analysis revealed a de novo heterozygous stop mutation (c.348C > A, p.Y116*) in exon 4 of the SYNGAP1 gene.

Discussion The main clinical features of our patient (i.e., intellectual disability and idiopathic epilepsy) are compatible with previous reports on patients with SYNGAP1 mutations. The unusual feature of complete EEG normalization with eye opening has not been reported yet for this genetic abnormality. Furthermore, our case provides further support for efficacy of VPA in patients with SYNGAP1 mutation–related epilepsy.

• References

• 1 Lemke JR, Riesch E, Scheurenbrand T , et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 2012; 53 (8) 1387-1398
  CrossrefPubMedGoogle Scholar
• 2 Scheffer IE. Epilepsy genetics revolutionizes clinical practice. Neuropediatrics 2014; 45 (2) 70-74
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Brodie MJ, Covanis A, Gil-Nagel A , et al. Antiepileptic drug therapy: does mechanism of action matter?. Epilepsy Behav 2011; 21 (4) 331-341
  CrossrefPubMedGoogle Scholar
• 4 Hildebrand MS, Dahl HH, Damiano JA, Smith RJ, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy. J Med Genet 2013; 50 (5) 271-279
  CrossrefPubMedGoogle Scholar
• 5 Kim JH, Liao D, Lau LF, Huganir RL. SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family. Neuron 1998; 20 (4) 683-691
  CrossrefPubMedGoogle Scholar
• 6 Kim JH, Lee HK, Takamiya K, Huganir RL. The role of synaptic GTPase-activating protein in neuronal development and synaptic plasticity. J Neurosci 2003; 23 (4) 1119-1124
  PubMedGoogle Scholar
• 7 Clement JP, Aceti M, Creson TK , et al. Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell 2012; 151 (4) 709-723
  CrossrefPubMedGoogle Scholar
• 8 Hamdan FF, Daoud H, Piton A , et al. De novo SYNGAP1 mutations in nonsyndromic intellectual disability and autism. Biol Psychiatry 2011; 69 (9) 898-901
  CrossrefPubMedGoogle Scholar
• 9 Berryer MH, Hamdan FF, Klitten LL , et al. Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. Hum Mutat 2013; 34 (2) 385-394
  CrossrefPubMedGoogle Scholar
• 10 Writzl K, Knegt AC. 6p21.3 microdeletion involving the SYNGAP1 gene in a patient with intellectual disability, seizures, and severe speech impairment. Am J Med Genet A 2013; 161A (7) 1682-1685
  PubMedGoogle Scholar
• 11 Zollino M, Gurrieri F, Orteschi D, Marangi G, Leuzzi V, Neri G. Integrated analysis of clinical signs and literature data for the diagnosis and therapy of a previously undescribed 6p21.3 deletion syndrome. Eur J Hum Genet 2011; 19 (2) 239-242
  CrossrefPubMedGoogle Scholar
• 12 Klitten LL, Møller RS, Nikanorova M, Silahtaroglu A, Hjalgrim H, Tommerup N. A balanced translocation disrupts SYNGAP1 in a patient with intellectual disability, speech impairment, and epilepsy with myoclonic absences (EMA). Epilepsia 2011; 52 (12) e190-e193
  CrossrefPubMedGoogle Scholar
• 13 Carvill GL, Heavin SB, Yendle SC , et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013; 45 (7) 825-830
  CrossrefPubMedGoogle Scholar
• 14 Hamdan FF, Gauthier J, Spiegelman D , et al; Synapse to Disease Group. Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N Engl J Med 2009; 360 (6) 599-605
  CrossrefPubMedGoogle Scholar
• 15 de Ligt J, Willemsen MH, van Bon BW , et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012; 367 (20) 1921-1929
  CrossrefPubMedGoogle Scholar
• 16 Vissers LE, de Ligt J, Gilissen C , et al. A de novo paradigm for mental retardation. Nat Genet 2010; 42 (12) 1109-1112
  CrossrefPubMedGoogle Scholar

• Supplementary Material